Premarket Dose Optimization Precedent In Oncology Likely Not Available Yet

The current crop of cancer drug approvals were well along in development when Project Optimus launched, meaning they may not have been able to implement the Oncology Center of Excellence’s premarket dose optimization policy.

Mirat Shah at the Friends of Cancer Research Annual Meeting
The FDA's Mirat Shah discusses Project Optimus during the Friends of Cancer Research Annual Meeting. • Source: Screenshot of internet broadcast

The current class of oncology drug approvals may not be the best example of the US Food and Drug Administration’s evolving approach to dose optimization policy.

Agency officials began pushing oncology sponsors more than a year ago to change from looking for the maximum tolerated dose...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Approval Standards

More from Pathways & Standards